This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Disorders of purine and pyrimidine metabolism
E4_PURINEPYRI
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpoints |
234 |
6. Filter based on genotype QC (FinnGen only) |
210 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E70-E90
- Name in latin
- Perturbationes metabolismi purini et pyrimidini
Similar endpoints
↥List of similar endpoints to
Disorders of purine and pyrimidine metabolism
based on the number of shared cases.
Similar with more cases:
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 210 | 84 | 126 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | 65.74 | 64.24 | 66.75 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 217
- Matched controls
- 2170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E79.0
ICD-10 Finland
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
+∞
239.2
183
*
M04AA01
ATC
allopurinol; systemic
14.2
90.3
129
203
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
12.1
46.1
52
55
M10.9
ICD-10 Finland
Gout, unspecified
8.9
41.0
60
89
M10.0
ICD-10 Finland
Idiopathic gout
10.4
28.5
34
38
N17.9
ICD-10 Finland
Acute renal failure, unspecified
11.4
26.2
29
29
C03CA01
ATC
furosemide; systemic
3.7
20.2
114
500
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
7.9
19.1
28
40
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.2
18.8
35
65
205
Kela drug reimbursment
Chronic hypertension
3.5
18.1
94
386
E79.9
ICD-10 Finland
Disorder of purine and pyrimidine metabolism, unspecified
+∞
18.0
17
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.3
17.3
53
151
M13.9
ICD-10 Finland
Arthritis, unspecified
5.6
17.1
36
75
H02AB06
ATC
prednisolone; systemic
3.5
17.0
143
779
A46
ICD-10 Finland
Erysipelas
3.9
16.6
60
192
E66.00
ICD-10 Finland
Metabolic syndrome
6.7
15.5
26
43
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.8
15.3
30
58
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
15.0
53
166
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
20.2
15.0
22
12
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.2
14.8
33
72
212
Kela drug reimbursment
Gout
13.3
14.5
25
21
P01BA02
ATC
hydroxychloroquine; oral
4.5
14.4
39
100
I50.9
ICD-10 Finland
Heart failure, unspecified
3.5
14.1
61
219
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
3.5
13.9
58
203
I10
ICD-10 Finland
Essential (primary) hypertension
3.4
13.8
168
1083
E79.8
ICD-10 Finland
Other disorders of purine and pyrimidine metabolism
+∞
13.7
13
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.5
13.5
28
57
A10BH05
ATC
linagliptin; oral
5.1
13.3
30
66
A07EC01
ATC
sulfasalazine; oral, rectal
4.6
12.6
33
82
J01FF01
ATC
clindamycin; systemic
2.9
12.6
86
399
C07AB07
ATC
bisoprolol; oral
2.9
12.6
140
838
C03DA01
ATC
spironolactone; oral
3.7
12.5
46
147
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
12.4
138
824
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
12.4
87
410
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.0
12.3
28
62
C10AA01
ATC
simvastatin; oral
2.8
12.2
116
638
C08CA01
ATC
amlodipine; oral
2.7
12.1
114
624
L28
ICPC
Limited function/disability (L)
3.0
11.9
67
279
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
4.0
11.6
37
107
J01DB01
ATC
cefalexin; oral
4.6
11.6
196
1456
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
11.4
67
284
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
26.7
11.3
15
6
288
Kela drug reimbursment
Febuxostat
45.8
11.0
13
*
103
Kela drug reimbursment
Diabetes, insulin-treated
2.7
10.8
83
405
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.8
10.7
75
348
A10BK01
ATC
dapagliflozin; oral
4.4
10.7
29
74
A10BA02
ATC
metformin; oral
2.7
10.6
84
415
H02AB07
ATC
prednisone; oral
3.3
10.6
46
163
C10AA05
ATC
atorvastatin; oral
2.6
10.6
114
654
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.6
10.5
39
125
T90
ICPC
Diabetes non-insulin dependent
2.7
10.4
74
346
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
24.8
10.4
14
6
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.9
10.4
33
95
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.2
10.3
47
172
G47.3
ICD-10 Finland
Sleep apnoea
2.7
10.2
70
321
M04AA03
ATC
febuxostat; oral
42.2
10.1
12
*
E86
ICD-10 Finland
Volume depletion
42.2
10.1
12
*
349
Kela drug reimbursment
Febuxostat
42.2
10.1
12
*
N18.8
ICD-10 Finland
Other chronic renal failure
11.4
10.0
18
17
E66.01
ICD-10 Finland
Obesity due to excess calories
4.1
9.8
29
79
N19
ICD-10 Finland
Unspecified kidney failure
7.8
9.8
22
31
I50.0
ICD-10 Finland
Congestive heart failure
3.8
9.8
33
99
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.7
9.6
69
323
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.6
9.5
35
111
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
5.1
9.5
21
45
R50.9
ICD-10 Finland
Fever, unspecified
3.0
9.4
50
199
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.2
9.3
26
68
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.6
9.1
72
351
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
9.1
42
154
A02BC02
ATC
pantoprazole; systemic
2.8
9.0
169
1218
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
5.2
9.0
19
39
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
3.2
8.9
39
138
AN1
HP
Coronary angiography
3.3
8.7
36
123
L04AX03
ATC
methotrexate; systemic
3.3
8.7
36
123
A10AC01
ATC
insulin (human); parenteral
3.8
8.7
28
81
M01AB01
ATC
indometacin; systemic, rectal
3.5
8.6
32
102
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
8.6
56
248
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
3.9
8.6
27
77
N02AX02
ATC
tramadol; systemic, rectal
2.3
8.5
113
691
C02AC05
ATC
moxonidine; oral
5.0
8.5
19
41
C09CA03
ATC
valsartan; oral
3.4
8.4
32
104
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
8.3
93
528
WX722
NOMESCO Finland
PEEP
4.2
8.2
23
60
E87.5
ICD-10 Finland
Hyperkalaemia
34.8
8.1
10
*
E66.9
ICD-10 Finland
Obesity, unspecified
8.3
8.0
17
22
C08CA13
ATC
lercanidipine; oral
2.8
8.0
45
184
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
7.4
8.0
18
26
M10
ICD-10 Finland
Gout
4.5
7.9
20
48
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.4
7.9
14
13
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
7.9
49
211
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.4
7.6
68
348
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.2
7.5
31
106
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
9.9
7.4
14
15
A11CC03
ATC
alfacalcidol; systemic
11.4
7.4
13
12
A10AB05
ATC
insulin aspart; parenteral
3.6
7.4
26
80
E0000UV, ,
ATC
2.2
7.3
100
610
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
7.3
39
155
N06AX21
ATC
duloxetine; oral
3.2
7.3
31
108
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.7
7.2
24
71
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.6
7.2
47
207
E66.8
ICD-10 Finland
Other obesity
6.2
7.1
18
31
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.5
7.0
53
251
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.9
6.9
21
58
A41.9
ICD-10 Finland
Sepsis, unspecified
4.5
6.9
17
40
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.4
6.6
52
249
A10AE05
ATC
insulin detemir; parenteral
3.9
6.6
20
55
SPAT1254
SPAT
Administration of medicine
2.6
6.6
43
189
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.3
6.6
60
308
TPH07
NOMESCO Finland
Cathetrisation of artery
2.9
6.5
33
127
WW500
NOMESCO Finland
Blood transfusion
4.3
6.5
17
42
N17.8
ICD-10 Finland
Other acute renal failure
14.9
6.5
10
7
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.2
6.4
66
356
E87.6
ICD-10 Finland
Hypokalaemia
11.5
6.4
11
10
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.5
6.2
42
187
C07AG02
ATC
carvedilol; oral
3.5
6.2
22
68
ZXD05
NOMESCO Finland
Urgent procedure
2.2
6.2
70
391
L01BA01
ATC
methotrexate; systemic
5.9
6.1
16
29
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.6
6.1
38
163
N02AA05
ATC
oxycodone; systemic
2.3
6.1
57
295
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
151
494
7.76
48.37
6.5
2.7
405.27
351.44
umol/l
5.08
139
431
89
206
6.63
39.89
11.3
5.6
1.13
1.04
mmol/l
1.47
84
189
82
280
4.10
21.29
4.6
2.2
20.33
23.20
%
1.32
77
264
84
299
3.95
20.44
4.6
2.2
2.20
2.27
g/l
0.54
77
284
51
125
5.03
20.26
7.8
3.2
113.11
83.57
ng/l
1.21
45
108
82
293
3.89
19.75
4.7
3.6
0.79
0.82
mmol/l
1.93
75
279
155
846
3.91
19.29
8.7
4.6
33.07
35.47
g/l
4.98
150
791
87
330
3.73
19.09
4.6
2.2
10.75
13.11
umol/l
2.62
79
309
155
859
3.82
18.55
15.1
6.3
1.20
1.21
mmol/l
0.88
144
783
49
126
4.73
18.26
2.4
1.6
—
—
—
0
0
163
948
3.89
17.78
16.3
6.7
1.20
1.21
mmol/l
1.09
139
817
60
198
3.81
15.86
9.0
4.1
1.54
1.52
mmol/l
0.01
46
172
141
805
3.15
14.67
3.1
2.2
74.50
77.21
nmol/l
0.50
129
712
162
1050
3.14
12.57
16.3
10.8
4.57
4.10
e9/l
2.01
147
929
158
1014
3.05
12.40
10.1
7.4
11.63
11.83
umol/l
0.09
152
959
64
258
3.10
12.01
1.9
1.8
—
—
—
0
0
104
554
2.68
11.47
2.7
2.1
132.72
176.99
u/l
1.18
98
524
151
969
2.84
11.42
6.3
3.8
0.02
0.00
estimate
0.49
43
205
152
980
2.84
11.37
6.4
3.8
0.00
0.01
estimate
0.50
44
207
59
234
3.09
11.32
10.7
8.1
0.79
0.90
mmol/l
0.06
43
197
76
351
2.79
11.02
2.2
1.9
—
—
—
0
0
152
989
2.79
11.01
6.4
3.9
7.32
1.53
estimate
0.35
41
196
65
279
2.90
10.79
1.8
1.8
—
—
—
0
0
27
65
4.60
10.70
6.6
2.3
23.98
25.33
mmol/l
0.64
27
65
59
242
2.97
10.62
10.7
8.0
10.80
12.26
kpa
1.20
54
230
59
242
2.97
10.62
10.7
8.0
4.94
5.19
kpa
0.90
54
229
165
1139
2.87
10.30
10.0
5.1
7.23
6.76
mmol/l
1.69
159
1076
23
51
4.93
10.04
1.7
1.3
—
—
—
0
0
25
60
4.58
9.93
1.7
1.2
—
—
—
0
0
71
333
2.68
9.84
2.0
1.7
1311.07
1209.57
nmol/l
0.36
57
256
106
602
2.49
9.84
3.3
2.6
62.26
72.54
u/l
0.37
101
555
109
628
2.48
9.80
6.7
3.9
23.05
4.95
mg/mmol
2.59
86
382
133
840
2.51
9.76
2.6
2.1
80.58
96.81
pmol/l
4.15
84
442
110
641
2.45
9.59
6.1
3.3
3209.10
1250.13
ng/l
2.18
99
545
49
194
2.97
9.30
11.8
9.2
117.88
122.29
g/l
0.69
49
187
90
484
2.47
9.30
3.1
2.1
3.95
3.12
mg/l
1.65
79
423
24
59
4.45
9.25
2.4
1.6
—
—
—
0
0
66
309
2.63
9.10
1.5
1.3
23.35
12.08
u/ml
0.51
24
124
43
161
3.08
8.98
2.8
2.6
3.03
7.12
ug/l
1.85
34
147
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
40
5.11
8.77
3.9
2.1
0.22
0.40
iu/ml
1.71
12
22
22
54
4.42
8.48
1.9
1.7
—
—
—
0
0
35
120
3.29
8.43
5.5
3.8
1.91
1.92
mmol/l
0.00
23
93
21
51
4.45
8.20
1.4
1.3
—
—
—
0
0
93
532
2.31
8.12
5.6
3.1
0.56
0.35
e6/l
0.69
79
392
30
98
3.39
7.78
1.8
1.3
—
—
—
0
0
98
581
2.25
7.78
6.3
4.0
0.00
0.00
estimate
-0.00
39
179
22
58
4.11
7.74
2.0
1.7
—
—
—
0
0
99
592
2.24
7.67
2.1
1.7
20.37
20.88
nmol/l
0.11
90
487
176
1340
2.66
7.60
8.1
4.5
21.15
12.44
mm/h
7.88
169
1239
66
335
2.39
7.50
1.7
1.3
61.88
37.04
iu/ml
0.49
27
108
118
764
2.19
7.43
6.7
3.7
39.53
77.51
ng/l
0.44
97
579
120
787
2.17
7.26
5.5
2.7
209.70
142.23
ug/l
1.54
109
730
24
71
3.68
7.21
1.3
1.2
0.22
3.35
u/ml
—
5
8
104
653
2.14
6.95
3.9
3.3
2.35
2.35
mmol/l
0.17
99
584
18
35
5.51
6.49
5.7
2.3
17.03
16.29
%
0.36
18
35
115
766
2.07
6.42
6.4
3.8
3.12
0.02
estimate
0.50
33
171
12
13
9.69
6.37
2.7
1.2
1258.00
743.31
mg
0.34
12
13
22
67
3.54
6.33
1.6
1.3
0.05
0.00
g/l
0.48
22
61
16
39
4.35
6.20
1.9
1.6
—
—
—
0
0
36
149
2.70
6.18
4.7
2.6
38.04
63.19
ml/min/173m2
5.71
24
58
18
49
3.92
6.06
1.9
1.5
—
—
—
0
0
15
27
5.89
5.80
1.5
1.4
—
—
—
0
0
17
36
5.03
5.75
1.9
1.8
—
—
—
0
0
37
162
2.55
5.67
2.1
2.0
350.22
383.71
nmol/l
0.38
32
152
62
342
2.14
5.59
4.5
2.8
0.79
1.01
e6/l
0.47
44
191
15
29
5.47
5.50
3.3
2.0
32.80
32.24
pg
0.23
15
29
56
302
2.15
5.33
4.7
2.9
3.69
2.16
e6/l
0.65
36
150
16
44
3.85
5.31
1.7
1.5
—
—
—
0
0
15
31
5.12
5.23
5.2
1.7
11.46
6.23
pmol/l
1.43
15
31
20
66
3.24
5.09
1.5
1.2
0.00
0.00
g/l
-0.00
20
58
17
51
3.53
5.00
2.0
1.5
—
—
—
0
0
117
835
1.87
4.88
4.1
2.9
—
—
estimate
—
0
0
40
195
2.29
4.83
4.7
3.5
—
—
—
0
0
18
59
3.24
4.63
3.1
2.4
1.27
1.77
ratio
—
9
31
13
28
4.87
4.45
2.6
1.5
1.77
1.49
mmol/l
0.83
13
28
20
74
2.88
4.22
1.6
1.8
2.27
7.37
iu/ml
—
6
23
11
21
5.46
4.20
2.8
1.2
89.36
88.59
%
0.17
11
21
15
47
3.35
4.14
1.6
1.4
310.00
251.12
ug/g
—
8
28
60
362
1.91
4.10
1.5
1.2
0.71
1.85
u/ml
0.93
21
93
41
217
2.10
4.03
3.2
3.2
8.76
8.70
umol/l
0.01
36
196
69
438
1.84
4.02
7.1
4.2
1.02
1.02
kg/l
0.20
58
295
14
44
3.33
3.85
1.3
1.6
—
—
—
0
0
144
1144
1.77
3.79
4.5
3.3
62.55
49.17
u/l
1.25
135
1070
69
446
1.80
3.76
3.5
2.5
—
—
—
0
0
10
21
4.94
3.60
1.1
1.0
—
—
—
0
0
10
22
4.71
3.47
1.7
2.0
—
—
—
0
0
79
543
1.72
3.43
5.2
3.1
0.38
0.17
estimate
0.28
37
157
198
1766
2.38
3.39
40.1
16.2
26.81
26.14
mg/l
0.13
190
1471
10
23
4.50
3.35
1.3
1.4
—
—
—
0
0
28
137
2.20
3.35
4.0
3.6
421.00
200.73
ng/l
0.97
28
125
184
1605
1.96
3.22
6.4
5.0
2.02
1.95
mu/l
0.39
174
1446
8
16
5.15
3.08
1.3
1.4
—
—
—
0
0
61
403
1.71
3.01
3.4
2.9
2.48
2.45
mmol/l
0.56
56
362
8
18
4.57
2.82
2.0
1.6
—
—
—
0
0
5
6
8.49
2.76
1.0
1.3
—
—
—
0
0
9
25
3.71
2.60
1.3
1.2
—
—
—
0
0
8
20
4.11
2.59
2.6
1.9
—
—
—
0
0
8
20
4.11
2.59
2.6
1.9
—
—
—
0
0
8
20
4.11
2.59
2.6
1.9
—
—
—
0
0
6
11
5.57
2.56
1.2
1.3
—
—
—
0
0
155
1322
1.60
2.52
5.3
4.0
15.14
15.06
pmol/l
0.17
139
1196
7
16
4.48
2.49
1.3
1.2
—
—
—
0
0
8
21
3.91
2.49
1.9
2.0
—
—
—
0
0
6
12
5.11
2.42
1.2
1.3
—
—
—
0
0
10
33
3.13
2.39
1.4
1.3
—
—
—
0
0
10
33
3.13
2.39
1.4
1.3
—
—
—
0
0
5
8
6.36
2.38
1.4
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
8
6.36
2.38
1.0
1.5
—
—
—
0
0
5
8
6.36
2.38
1.0
1.0
—
—
—
0
0
57
394
1.61
2.32
2.0
1.7
485.94
441.36
pmol/l
0.44
51
326
6
13
4.71
2.28
1.2
1.2
—
—
—
0
0
6
13
4.71
2.28
1.3
1.2
—
—
—
0
0
6
13
4.71
2.28
1.2
1.2
—
—
—
0
0
6
13
4.71
2.28
2.3
1.9
—
—
—
0
0
6
13
4.71
2.28
1.3
1.1
—
—
—
0
0
7
18
3.98
2.27
1.4
1.2
—
—
—
0
0
16
74
2.25
2.21
2.4
3.2
—
—
—
0
0
23
124
1.96
2.17
2.1
1.7
—
—
—
0
0
7
19
3.77
2.17
4.0
2.8
—
—
—
0
0
6
14
4.37
2.16
1.2
1.2
—
—
—
0
0
6
14
4.37
2.16
1.5
1.1
—
—
—
0
0
5
10
5.09
2.08
1.0
1.0
145.80
356.90
u/l
—
5
10
6
15
4.08
2.05
3.0
2.7
—
—
—
0
0
11
44
2.58
2.04
1.6
1.2
—
—
—
0
0
50
346
1.58
2.01
4.6
3.9
891.93
341.07
ng/l
0.30
44
270
10
39
2.64
1.97
1.9
1.4
—
—
—
0
0
11
45
2.52
1.96
1.6
1.2
—
—
—
0
0
11
45
2.52
1.96
2.0
1.3
—
—
—
0
0
5
11
4.62
1.95
1.0
1.4
99.60
111.09
pmol/l
—
5
11
5
11
4.62
1.95
1.2
1.0
—
—
—
0
0
5
11
4.62
1.95
1.2
1.0
—
—
—
0
0
6
16
3.82
1.95
8.5
3.6
1.00
1.00
%
—
6
16
12
52
2.38
1.91
1.7
1.2
—
—
—
0
0
36
234
1.65
1.86
21.9
7.7
—
—
—
0
0
11
47
2.41
1.81
2.8
2.5
146.75
126.70
ug/min
—
6
25
34
221
1.64
1.76
4.3
5.2
4.47
53.36
ug/l
0.79
26
189
9
36
2.56
1.76
1.3
1.2
—
—
—
0
0
6
18
3.40
1.76
1.2
1.2
—
—
—
0
0
198
1846
1.83
1.75
49.6
19.6
4.01
4.00
mmol/l
0.22
193
1802
14
68
2.13
1.74
1.6
1.3
—
—
—
0
0
185
1697
1.61
1.71
10.4
6.4
42.44
39.29
mmol/mol
3.57
175
1572
11
49
2.31
1.66
5.4
3.3
2.40
2.20
index
—
5
30
27
170
1.67
1.58
1.7
1.9
1.62
1.48
%
0.27
18
150
6
21
2.91
1.51
2.7
1.5
—
—
—
0
0
6
21
2.91
1.51
7.2
2.4
5.03
3.65
nmol/l
—
6
21
92
755
1.38
1.51
2.3
2.0
1.63
1.30
mmol/l
2.84
82
621
110
931
1.37
1.48
3.2
2.7
—
—
—
0
0
53
396
1.45
1.48
3.4
1.8
1.61
1.53
mg/l
0.08
39
312
6
22
2.77
1.44
1.5
1.1
—
—
—
0
0
6
23
2.65
1.37
1.0
1.0
—
—
—
0
0
5
17
2.98
1.36
1.0
1.1
—
1.54
—
0
5
5
19
2.67
1.22
1.0
1.4
—
—
—
0
0
8
40
2.04
1.13
3.5
2.2
218.00
216.72
e6/l
—
8
32
184
1727
1.43
1.09
6.8
5.3
6.44
5.99
mmol/l
3.60
167
1566
6
30
2.03
0.87
1.0
1.1
—
—
—
0
0
8
44
1.85
0.87
1.5
1.3
—
—
—
0
0
8
45
1.81
0.85
1.4
1.6
—
—
—
0
0
8
45
1.81
0.85
1.5
1.3
—
1.03
—
0
6
6
31
1.96
0.85
1.5
1.6
—
—
—
0
0
10
58
1.76
0.81
2.9
1.8
—
—
—
0
0
0
27
0.00
0.78
0.0
1.3
—
1.05
—
0
17
6
34
1.79
0.77
1.3
1.3
470.83
314.12
mu/l
—
6
34
180
1711
1.31
0.74
34.8
15.9
64.69
77.34
ml/min/173m2
8.63
173
1606
187
1790
1.32
0.70
7.7
5.8
2.39
2.67
mmol/l
3.78
176
1638
10
62
1.64
0.66
3.6
2.1
—
—
—
0
0
14
95
1.51
0.66
3.0
9.2
1.60
1.58
%
0.03
14
86
8
50
1.62
0.62
1.5
1.4
—
2.81
—
0
10
6
36
1.69
0.57
1.8
1.2
—
—
—
0
0
13
90
1.47
0.57
2.2
3.8
20.08
2009.58
u/ml
0.82
13
73
6
38
1.60
0.55
1.0
1.1
—
4.72
—
0
5
183
1761
1.25
0.54
6.8
5.1
4.27
4.56
mmol/l
3.09
172
1619
182
1753
1.24
0.51
6.7
5.0
1.28
1.45
mmol/l
6.54
170
1599
175
1681
1.21
0.49
5.9
4.2
1.73
1.24
mmol/l
9.24
160
1521
5
31
1.63
0.43
1.6
1.8
13.20
10.90
mmol/l
—
5
31
5
31
1.63
0.43
2.0
1.9
—
—
—
0
0
89
829
1.12
0.34
4.7
5.8
2.51
2.77
ug/l
0.16
78
740
7
99
0.70
0.31
1.6
2.2
—
—
—
0
0
45
499
0.88
0.30
3.5
3.3
0.74
0.74
ug/l
0.01
40
338
19
158
1.22
0.29
1.6
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
4.17
—
0
6
29
260
1.13
0.20
5.4
4.8
27.77
32.73
%
1.99
22
162
26
234
1.13
0.17
1.6
1.5
—
—
—
0
0
7
90
0.77
0.14
1.6
2.1
—
—
—
0
0
64
669
0.94
0.13
4.5
4.9
22.55
21.42
%
0.27
38
355
5
46
1.09
0.09
1.4
1.4
—
—
—
0
0
7
80
0.87
0.07
1.3
1.0
—
—
—
0
0
145
1431
1.04
0.07
53.2
22.1
329.98
332.12
g/l
1.73
145
1424
12
110
1.10
0.05
1.2
1.3
—
34.96
—
0
11
17
176
0.96
0.00
1.5
1.5
—
—
—
0
0
18
185
0.97
0.00
2.2
2.5
9.15
14.14
nmol/l
1.50
13
172
0
7
0.00
-0.00
0.0
1.1
—
51.92
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
7.83
—
0
9
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
52.49
—
0
8
0
5
0.00
-0.00
0.0
1.6
—
7.82
—
0
5
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: E4_PURINEPYRI – Disorders of purine and pyrimidine metabolism
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).